Key result
Mitral surgery in endstage cardiomyopathy yields ~7% 30-day mortality, well below EuroSCORE-predicted risk.
Why the study?
Outcomes after mitral valve surgery in patients with severe mitral incompetence and endstage cardiomyopathy with ejection fraction below 30% were not well characterized.
Cohort (n=42)
Absolute Event Rate: 7.14% vs 33.41%
Mitral valve surgery may warrant consideration in selected end-stage cardiomyopathy patients; leaves open need for prospective trials versus modern medical therapy.
We retrospectively investigated 42 patients (27 men, 15 women; mean age, 67 years) with severe mitral valve incompetence and endstage cardiomyopathy (ejection fraction<30%) who were operated on between January 2002 and March 2009. Of these, 14 were in New York Heart Association class IV, and 27 were in class III. The etiology was ischemic in 18 patients and idiopathic dilated in 24. Mitral valve repair was performed in 25 patients, and 17 had mitral valve replacement. The mean logistic EuroSCORE was 33.41. The mean follow-up was 44.52 months. There were no perioperative deaths. Three patients died within 30 days postoperatively. Thirty-day mortality was lower than predicted by EuroSCORE (7.14% vs. 33.41%). The median functional class improved from 3 to 2 during follow-up. Ejection fraction improved from 24% to 42% at 6 weeks, then decreased to 33%. The midterm survival rate was 86%, and 81% after 1 and 2 years. Freedom from reoperation at 2 years was 85%; 6 patients needed reoperation for recurrent mitral regurgitation. Despite high operative risk, mitral valve surgery can be performed successfully with acceptably low mortality in patients with endstage cardiomyopathy. Patients experience substantial clinical improvement and a moderate recovery of left ventricular function.
No takes yet. Share an insight, caveat, or question.
Parker et al. (2012) conducted a cohort in Severe mitral valve incompetence and endstage cardiomyopathy (n=42). Mitral valve operations (repair or replacement) vs. Logistic EuroSCORE predicted mortality was evaluated on 30-day mortality. Mitral valve operations in patients with endstage cardiomyopathy resulted in a 30-day mortality of 7.14%, which was lower than the 33.41% mortality predicted by the logistic EuroSCORE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: